Log in

Cortexyme Stock Forecast, Price & News

+0.65 (+1.35 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $48.84
50-Day Range
MA: $46.17
52-Week Range
Now: $48.84
Volume64,367 shs
Average Volume138,961 shs
Market Capitalization$1.44 billion
P/E RatioN/A
Dividend YieldN/A
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryHealth Care Technology
Current SymbolNASDAQ:CRTX



Sales & Book Value

Annual SalesN/A
Book Value$4.30 per share


Net Income$-36,980,000.00


Market Cap$1.44 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
+0.65 (+1.35 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cortexyme (NASDAQ:CRTX) Frequently Asked Questions

How has Cortexyme's stock been impacted by Coronavirus (COVID-19)?

Cortexyme's stock was trading at $37.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRTX shares have increased by 31.9% and is now trading at $48.84.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Cortexyme?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cortexyme

When is Cortexyme's next earnings date?

Cortexyme is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Cortexyme

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) posted its earnings results on Monday, August, 17th. The biopharmaceutical company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.62) by $0.02.
View Cortexyme's earnings history

What price target have analysts set for CRTX?

3 Wall Street analysts have issued 12-month target prices for Cortexyme's shares. Their forecasts range from $59.00 to $76.00. On average, they anticipate Cortexyme's stock price to reach $68.33 in the next year. This suggests a possible upside of 39.9% from the stock's current price.
View analysts' price targets for Cortexyme

Who are some of Cortexyme's key competitors?

What other stocks do shareholders of Cortexyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include ADMA Biologics (ADMA), Gran Tierra Energy (GTE), BioNano Genomics (BNGO), DHT (DHT), EnLink Midstream (ENLC), Golar LNG Partners (GMLP), Matinas BioPharma (MTNB), OrganiGram (OGI), Pennsylvania R.E.I.T. (PEI) and Tilly's (TLYS).

Who are Cortexyme's key executives?

Cortexyme's management team includes the following people:
  • Ms. Casey C. Lynch, Co-Founder, Chairman, Pres & CEO (Age 45)
  • Mr. Stephen S. Dominy, Co-Founder, Chief Scientific Officer & Director (Age 63)
  • Ms. Kristen Gafric, Co-Founder, Sr. VP of Legal & Admin. and Sec. (Age 43)
  • Mr. Christopher P. Lowe, CFO & Treasurer (Age 48)
  • Dr. Michael J. Detke, Chief Medical Officer (Age 52)

When did Cortexyme IPO?

(CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Who are Cortexyme's major shareholders?

Cortexyme's stock is owned by a variety of retail and institutional investors. Top institutional investors include EPIQ Capital Group LLC (11.36%), Vanguard Group Inc. (2.04%), Bank of New York Mellon Corp (0.26%), Nuveen Asset Management LLC (0.25%), Marshall Wace North America L.P. (0.20%) and Charles Schwab Investment Management Inc. (0.19%). Company insiders that own Cortexyme stock include David Lamond, Epiq Capital Group, Llc and Pfizer Inc.
View institutional ownership trends for Cortexyme

Which institutional investors are selling Cortexyme stock?

CRTX stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., UBS Group AG, Virtus ETF Advisers LLC, and Bank of America Corp DE.
View insider buying and selling activity for Cortexyme

Which institutional investors are buying Cortexyme stock?

CRTX stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., EPIQ Capital Group LLC, Goldman Sachs Group Inc., SG Americas Securities LLC, Swiss National Bank, Nuveen Asset Management LLC, Marshall Wace North America L.P., and Bank of New York Mellon Corp. Company insiders that have bought Cortexyme stock in the last two years include David Lamond, Epiq Capital Group, Llc, and Pfizer Inc.
View insider buying and selling activity for Cortexyme

How do I buy shares of Cortexyme?

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $48.84.

How big of a company is Cortexyme?

Cortexyme has a market capitalization of $1.44 billion. The biopharmaceutical company earns $-36,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cortexyme employs 16 workers across the globe.

What is Cortexyme's official website?

The official website for Cortexyme is www.cortexyme.com.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.